Unique targeting of PPARβ/δ regulation for cancer prevention and therapy
癌症预防和治疗中 PPARβ/β 调节的独特靶向
基本信息
- 批准号:10539245
- 负责人:
- 金额:$ 64.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-12-06 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:APC geneAcuteAntineoplastic AgentsBioinformaticsBiological MarkersBreast Cancer ModelCancer ModelCancer cell lineCellsColonColon CarcinomaColorectal CancerComplexCoupledDataDatabasesDiseaseDisputesDoseDown-RegulationDrug KineticsDrug TargetingDrug resistanceEpitheliumEvaluationEventExhibitsFecesGene ExpressionGenesGeneticGenetic TranscriptionGenomicsGenotypeGoalsGrowth Factor ReceptorsHistologyHumanImmune checkpoint inhibitorInvadedKRAS2 geneLigandsLinkMalignant NeoplasmsMetabolicMetabolic PathwayMetabolismMethodologyModelingMolecularMolecular TargetMorbidity - disease rateMutationMutation SpectraNU/NU MouseNeoplasm MetastasisNodalNuclear ReceptorsPPAR-betaPathway interactionsPeroxisome Proliferator-Activated ReceptorsPharmaceutical PreparationsPhasePre-Clinical ModelPreventionProto-OncogenesRecurrenceRecurrent diseaseRegulationRepressionResearchResistanceRoleScientistStudy modelsSystems AnalysisTP53 geneTestingTherapeuticTimeTissuesToxic effectTranslational ResearchTumor PromotionTumor Suppressor ProteinsUnited StatesVariantanti-cancercancer cellcancer heterogeneitycancer preventioncancer therapycancer typecolon cancer patientscolon cancer preventioncolorectal cancer preventioncolorectal cancer progressioncolorectal cancer treatmentcombinatorialconstitutive expressiondosimetrydrug efficacyeffective therapyefficacy evaluationfightinggain of functiongene repressiongenetic corepressorimprovedinhibitorinnovationinsightloss of functionmetabolomicsmigrationnovelnovel markernovel strategiesoverexpressionpersonalized approachpreventreceptorrecruitrefractory cancerstemnesstranscription factortranslational impacttumortumor progressiontumorigenesisweb platform
项目摘要
Project Summary: Precision approaches for inhibiting, preventing recurrence, or treating cancers remains a
top priority in the US. While different inhibitors have made significant improvements for these purposes (e.g.
immune checkpoint inhibitors, growth factor receptor inhibitors, etc.), it is clear that additional molecular targets
are needed to combine with these existing therapies due to the heterogeneity of cancers and the fact that
many cancers are resistant to different inhibitors. Thus, delineating new molecular mechanisms for
combinatorial approaches for more precision inhibition and therapy of cancer is of high significance. The
peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) has great potential as a molecular target for
preventing and/or treating colorectal cancer (CRC). Typical ligands for PPARβ/δ increase and decrease target
gene expression. However, more selective, repressive PPARβ/δ ligands have recently been developed that
only repress gene expression rather than increase target genes. These selective repressive PPARβ/δ ligands
can markedly inhibit cellular events associated with cancer inhibition, progression and metastasis. There is no
dispute that selective, repressive PPARβ/δ ligands are effective anti-cancer molecules. These facts and
preliminary data provide strong support and rigor of the central hypothesis of this proposal that
repressing PPARβ/δ target genes by a selective, repressive ligand can modulate CRC and may be
targeted for precision approaches to inhibit/treat CRC. This hypothesis will be examined by 3 Aims. Aim 1
will include PK analysis of the selective, repressive PPARβ/δ ligand DG172 of tissue concentrations over time,
and phase I and phase II metabolism of the selective, repressive PPARβ/δ ligand in tissues, biofluids and
tumors. Aim 2 will determine the efficacy of the selective, repressive PPARβ/δ ligand DG172 to inhibit
tumorigenesis and stemness in novel orthotopic tumors models that utilize unique, genotypically variant human
cancer cell lines with genotypes that exhibit resistance to standard inhibitors used to treat CRC, and gain- and
loss-of-function models for PPARβ/δ. The mechanisms by which PPARβ/δ regulates stemness will also be
determined. For Aim 3, we will integrate genomic and metabolomic bioinformatic analyses to elucidate how
specific metabolic and tumor-promoting pathways that can be targeted by selective repressive PPARβ/δ
ligands to inhibit CRC progression and treat CRC. Data from Aim 3 will be made available to scientists by
developing a web-based platform to allow for systems analyses of PPARβ/δ-specific pathways that inhibit
CRC. Results from these studies will have a sustained impact as they will provide new PPARβ/δ-dependent
targets that might be combined with other inhibitors to develop more effective therapies, and prevent
recurrence, for CRC.
项目摘要:抑制、预防或治疗癌症的精确方法仍然是一个
这是美国的首要任务。虽然不同的抑制剂已经在这些目的上取得了显著的改进(例如,
免疫检查点抑制剂、生长因子受体抑制剂等),很明显,额外的分子靶点
由于癌症的异质性和事实,需要与这些现有的治疗方法相结合
许多癌症对不同的抑制剂具有抗药性。因此,描绘了新的分子机制
组合方法对于更精确地抑制和治疗癌症具有重要意义。这个
过氧化物酶体增殖物激活受体β/δ(PPARβ/δ)是一种很有潜力的分子靶标。
预防和/或治疗结直肠癌。PPARβ/δ增减靶标的典型配体
基因表达。然而,最近开发出了更具选择性、抑制性的PPARβ/δ配体
只抑制基因表达,而不是增加靶基因。这些选择性抑制的PPARβ/δ配体
能显著抑制与癌症抑制、进展和转移相关的细胞事件。没有
质疑选择性的、抑制性的PPARβ/δ配体是有效的抗癌分子。这些事实和
初步数据为这一提议的中心假设提供了强有力的支持和严谨性
通过选择性抑制配体抑制PPARβ/δ靶基因可以调节结直肠癌,并可能是
针对抑制/治疗CRC的精确方法。这一假设将由三个目标来检验。目标1
将包括对选择性、抑制性PPARβ/δ配体DG172随时间组织浓度的PK分析,
以及选择性的、抑制性的PPARβ/δ配体在组织、生物液和
肿瘤。目的2将确定选择性、抑制性PPARβ/δ配体DG172的抑制效果
利用独特的、基因变异的人类的新型原位肿瘤模型的肿瘤发生和干性
对用于治疗结直肠癌的标准抑制剂表现出抗药性的基因的癌细胞株,以及Gain-And
PPARβ/δ的功能损失模型。PPARβ/δ调节茎干的机制也将是
下定决心。对于目标3,我们将整合基因组和代谢生物信息学分析,以阐明如何
选择性抑制性PPARβ/δ靶向的特定代谢和促肿瘤通路
用来抑制CRC进展和治疗CRC的配体。来自AIM 3的数据将通过以下方式提供给科学家
开发一个基于网络的平台,以允许对抑制PPARβ/δ的特定途径进行系统分析
CRC。这些研究的结果将产生持续的影响,因为它们将提供新的依赖于β/δ的PPAR
靶点,可能与其他抑制剂结合,以开发更有效的治疗方法,并防止
复发,用于CRC。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Patterson其他文献
Andrew Patterson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Patterson', 18)}}的其他基金
Environmental Chemical Impact on the Host-Microbiome Interaction
环境化学对宿主-微生物组相互作用的影响
- 批准号:
10641509 - 财政年份:2023
- 资助金额:
$ 64.15万 - 项目类别:
Integrative Analysis of Metabolic Phenotypes (IAMP) Predoctoral Training Program
代谢表型综合分析(IAMP)博士前培训项目
- 批准号:
10417044 - 财政年份:2020
- 资助金额:
$ 64.15万 - 项目类别:
Integrative Analysis of Metabolic Phenotypes (IAMP) Predoctoral Training Program
代谢表型综合分析(IAMP)博士前培训项目
- 批准号:
10626745 - 财政年份:2020
- 资助金额:
$ 64.15万 - 项目类别:
Unique targeting of PPARβ/δ regulation for cancer prevention and therapy
癌症预防和治疗中 PPARβ/β 调节的独特靶向
- 批准号:
10311068 - 财政年份:2019
- 资助金额:
$ 64.15万 - 项目类别:
Unique targeting of PPARβ/δ regulation for cancer prevention and therapy
癌症预防和治疗中 PPARβ/β 调节的独特靶向
- 批准号:
10066327 - 财政年份:2019
- 资助金额:
$ 64.15万 - 项目类别:
Unique targeting of PPARβ/δ regulation for cancer prevention and therapy
癌症预防和治疗中 PPARβ/β 调节的独特靶向
- 批准号:
9906573 - 财政年份:2019
- 资助金额:
$ 64.15万 - 项目类别:
R01: FXR and the Gut Microbiome as Modulators of Non-Alcoholic Fatty Liver Disease
R01:FXR 和肠道微生物组作为非酒精性脂肪肝的调节剂
- 批准号:
10228735 - 财政年份:2019
- 资助金额:
$ 64.15万 - 项目类别:
R01: FXR and the Gut Microbiome as Modulators of Non-Alcoholic Fatty Liver Disease
R01:FXR 和肠道微生物组作为非酒精性脂肪肝的调节剂
- 批准号:
10488612 - 财政年份:2019
- 资助金额:
$ 64.15万 - 项目类别:
R01: FXR and the Gut Microbiome as Modulators of Non-Alcoholic Fatty Liver Disease
R01:FXR 和肠道微生物组作为非酒精性脂肪肝的调节剂
- 批准号:
10671560 - 财政年份:2019
- 资助金额:
$ 64.15万 - 项目类别:
R01: FXR and the Gut Microbiome as Modulators of Non-Alcoholic Fatty Liver Disease
R01:FXR 和肠道微生物组作为非酒精性脂肪肝的调节剂
- 批准号:
10022323 - 财政年份:2019
- 资助金额:
$ 64.15万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 64.15万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 64.15万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 64.15万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 64.15万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 64.15万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 64.15万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 64.15万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 64.15万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 64.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 64.15万 - 项目类别:
Standard Grant